A5056456006- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Colorectal and Anal Carcinomas
- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Lymphoma Diagnosis and Treatment
- Microscopic Colitis
- Hidradenitis Suppurativa and Treatments
- Asthma and respiratory diseases
- CNS Lymphoma Diagnosis and Treatment
- Rheumatoid Arthritis Research and Therapies
- Neurological Disorders and Treatments
- Autoimmune and Inflammatory Disorders Research
Iwate Medical University
2025
ABB (Japan)
2018-2020
AbbVie (Japan)
2018-2020
Abstract Risankizumab, a humanized immunoglobulin G1 monoclonal antibody, selectively inhibits interleukin‐23, key cytokine in the pathogenesis of psoriasis, by binding to its p19 subunit. In Susta IMM (ClinicalTrials.gov/NCT03000075), phase 2/3, double‐blinded, placebo‐controlled study, Japanese patients with moderate severe plaque psoriasis ( n = 171) were stratified bodyweight and concomitant psoriatic arthritis randomized 2:2:1:1 75 mg risankizumab, 150 placebo cross‐over risankizumab...
Abstract A phase 3, multicenter, open‐label, 52‐week study investigated the efficacy and safety of adalimumab 80 mg at week 0 followed by 40 every other (option to escalate when necessary) in Japanese patients with generalized pustular psoriasis (GPP). Adults (aged 15–75 years) GPP, total skin score (overall erythema area, area pustules, edema area) 3 or more, pustules (skin score, ≥1) based on 2014 Dermatological Association severity index GPP were enrolled. The primary end‐point was...
Abstract Objective To evaluate upadacitinib efficacy and safety dose response in Japanese patients with active RA an inadequate to conventional synthetic DMARDs (csDMARDs). Methods This was a multicentre, phase IIb/III, dose-ranging study conducted Japan, which on previously stable csDMARDs were randomized receive 7.5, 15 or 30 mg once daily matching placebo for 12-week double-blind period. The primary endpoint 20% improvement ACR criteria (ACR20) at week 12 using non-responder imputation....
The prognostic value of models such as the international index (IPI) in patients with malignant lymphomas treated a combination rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone is well established. However, whether these apply to tetrahydropyranyl adriamycin, (R-THP-COP) unclear. This retrospective analysis included 101 Diffuse large B-cell lymphoma (DLBCL) R-THP-COP. primary endpoint was overall survival (OS). secondary endpoints were progression-free (PFS), complete...
This phase 3, multicenter, open-label single-arm study evaluated adalimumab (ADA) in Japanese patients with moderate to severe hidradenitis suppurativa (HS). Fifteen received ADA 160 mg s.c. at week 0, 80 2 and 40 4 every thereafter. At any time after 52, were given the option receive other or remain on week. The primary end-point (achievement of HS Clinical Response [HiSCR] 24) results up 24 published previously. Secondary end-points included total abscess inflammatory nodule (AN) count,...
Abstract Hidradenitis suppurativa ( HS ) is a chronic skin disease characterized by recurrent painful inflamed nodules/abscesses and draining fistulas that negatively impact quality of life. Adalimumab, monoclonal antibody against tumor necrosis factor‐α, has been approved in the EU, USA Japan for treatment moderate to severe . This an interim analysis ongoing phase 3, multicenter, open‐label, single‐arm study safety efficacy adalimumab weekly dosing Japanese patients with Fifteen received...
<h3>Background</h3> Upadacitinib (UPA) is an oral, JAK1-selective inhibitor found to be effective in Phase 2 and 3 studies rheumatoid arthritis (RA) patients with inadequate response or intolerance csDMARDs bDMARDs.<sup>1–4</sup> <h3>Objectives</h3> To evaluate the efficacy safety of UPA Japanese active RA (csDMARD-IR). <h3>Methods</h3> During 12 week double-blind period, on stable were randomised receive 7.5,15 30 mg once daily PBO (1:1:1:1). The primary endpoint was proportion achieving...